<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</h2>
    <div class="badge">2025-09-08T15:00:00+00:00</div>
    <ul>
      <li>2021 Jan 14;7(1):3.</li>
<li>Sci Rep 15, 23495 (2025).</li>
<li>2014 Oct 21;121(5):664–672.</li>
<li>Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.</li>
<li>The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu</li>
<li>About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading</li>
<li>doi: 10.1038/s41572-020-00235-0.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=First%20Disclosure%20of%20Global%20Interim%20Phase%202%20Data%20for%20BioNTech%20and%20Bristol%20Myers%20Squibb%20PD-L1xVEGF-A%20Bispecific%20Antibody%20Pumitamig%20%28BNT327%2FBMS986545%29%20in%20Patients%20with%20Extensive-Stage%20Small%20Cell%20Lung%20Cancer%20Shows%20Encouraging%20Antitumor%20Activity%0A%E2%80%A2%202021%20Jan%2014%3B7%281%29%3A3.%0A%E2%80%A2%20Sci%20Rep%2015%2C%2023495%20%282025%29.%0A%E2%80%A2%202014%20Oct%2021%3B121%285%29%3A664%E2%80%93672.%0A%E2%80%A2%20Food%20and%20Drug%20Administration%20%28%E2%80%9CFDA%E2%80%9D%29%20for%20the%20treatment%20of%20patients%20with%20small%20cell%20lung%20cancer%20in%202025.%0A%E2%80%A2%20The%205-year%20survival%20rate%20for%20patients%20with%20extensive-stage%20SCLC%20is%20only%205%25%2C%20emphasizing%20the%20need%20for%20new%20treatment%20options%20that%20extend%20progression-free%20survival.2%2C%203%20About%20pumitamig%20%28also%20known%20as%20BNT327%20or%20BMS986545%29%20Pu%0A%E2%80%A2%20About%20Small%20Cell%20Lung%20Cancer%20Small%20cell%20lung%20cancer%20%28SCLC%29%20accounts%20for%2015%25%20of%20all%20lung%20cancer%20cases%2C%20with%20an%20estimated%20250%2C000%20new%20cases%20globally%20per%20year.1%20It%20is%20the%20most%20aggressive%20type%20of%20lung%20cancer%20often%20spreading%0A%E2%80%A2%20doi%3A%2010.1038%2Fs41572-020-00235-0.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Ffirst-disclosure-of-global-interim-phase-2-data-for-biontech-and-bristol-myers-s%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>